Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levilactobacillus brevis KABP052
- Development stage
- Unknown
- Lead developer
- Kaneka
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Levilactobacillus brevis KABP052 is a proprietary probiotic bacterial strain with high β-glucuronidase activity, capable of deconjugating estrogen glucuronides in the gut to release free estrogens, which can then be reabsorbed systemically. It has been clinically tested as part of probiotic blends to support hormone balance in healthy peri- and postmenopausal women, where it helped maintain serum estradiol and estrone levels compared to placebo. KABP052 also shows antimicrobial activity against oral pathogens and can colonize the oral cavity, contributing to oral health by reducing plaque levels. It has been evaluated in both oral and gut health interventions and is considered safe and well-tolerated[1][2][3][4][5].
- Other names
- Levilactobacillus brevis KABP052L. brevis KABP052
02
Targets
GUSB (Beta-glucuronidase)
Beyond the preview
Go deeper on levilactobacillus brevis KABP052.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levilactobacillus brevis KABP052.